IGC PharmaIGC +0.42%29 Gross Margin % is 17.35% as of Mar. 2026, which is 32% below its 10-year median of 25.42. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Fairly Valued). The stock has 6 warning signs investors should review. Among 737 Biotechnology companies, IGC Pharma ranks worse than 76.39% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. IGC Pharma's Gross Profit for the
three
months ended in Mar. 2026 was $0.06 Mil. IGC Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.32 Mil. Therefore, IGC Pharma's Gross Margin % for the quarter that ended in Mar. 2026 was 17.35%.
The historical rank and industry rank for IGC Pharma's Gross Margin % or its related term are showing as below:
IGC'
s Gross Margin % Range Over the Past 10 Years
Min: 2.58 Med: 25.42 Max: 54.5
Current: 29.68
During the past 13 years, the highestGross Margin % of IGC Pharma was 54.50%. The lowest was 2.58%. And the median was 25.42%.
IGC's Gross Margin % is ranked worse than 76.39% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs IGC: 29.68
IGC Pharma had a gross margin of 17.35% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for IGC Pharma was 70.30% per year.
IGC Pharma (AMEX:IGC) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
IGC Pharma had a gross margin of 17.35% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
IGC Pharma Gross Margin % Related Terms
IGC Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC vs CRVO, NEUP, CELU: Gross Margin % Comparison
For the Biotechnology subindustry, IGC Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
IGC Pharma (IGC) has a Gross Margin % of 17.35% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on IGC Pharma and its competitors. This is 32% below median its historical median of 25.42. Over the past decade, IGC Pharma's Gross Margin % has ranged from 2.58 to 54.50. According to the industry distribution chart, IGC Pharma ranks #563 out of 737 companies in the Biotechnology industry, placing it in the top 76.4%.
Is IGC Pharma's Gross Margin % too high?
IGC Pharma's current Gross Margin % of 17.35% is 32% below median its 10-year median of 25.42. Over the past 10 years, this metric has ranged from a low of 2.58 to a high of 54.50. The Biotechnology industry median Gross Margin % is 60.92. IGC Pharma's value of 17.35% is 71.5% below this industry median. Based on the distribution chart, IGC Pharma ranks #563 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Gross Margin % compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #563 out of 737 companies for Gross Margin %. This places IGC Pharma in the lower half of its industry. The industry median Gross Margin % is 60.92. IGC Pharma's value of 17.35% is 71.5% below this benchmark. Historically, IGC Pharma's own Gross Margin % has ranged from 2.58 to 54.50 over the past decade. While the company's 10-year median is 25.42 vs. the industry median of 60.92, IGC Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Gross Margin % of 17.35% is 71.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Gross Margin % is 17.35%, which is 32% below median its own 10-year median of 25.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 9.6% above its estimated fair value. The current Gross Margin % is 17.35%, which is 32% below median its 10-year median of 25.42 and 71.5% below the Biotechnology industry median of 60.92. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For IGC Pharma (IGC), the current Gross Margin % is 17.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.26 is trading 9.6% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Fairly Valued.
Key valuation signals for IGC:
Gross Margin %: 17.35% (32% below median its 10-year median of 25.42)
GF Value™: $0.24 vs. price of $0.26 (9.6% above fair value)
Industry Position: 71.5% below the Biotechnology median (#563 of 737)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
